Trial · NCT00910299
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
NCT00910299, Phase 2, Terminated, Eli Lilly and Company; results first posted 2012-06-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI). Trials, record NCT00910299. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00910299
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)
- NCT number
- NCT00910299
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 423 participants, actual
- Lead sponsor
- Eli Lilly and Company
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- Prasugrel, Clopidogrel
- First posted
- 2009-05-29
- Last updated
- 2012-06-08
- Results first posted
- 2012-06-08
- Limitations and caveats
- The study was terminated early, and no formal statistical time-to-event analysis was performed.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Composite Endpoint of Cardiovascular Death or Myocardial Infarction (MI) | Baseline through 6 months | The endpoint in this measure is a combination of cardiovascular death or MI. |
| Secondary | Number of Participants With Stent Thrombosis (ST) | Baseline through 6 months | Academic Research Consortium (ARC) criteria was used to define ST. Definite ST is angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region, and at least one of the following additional criteria: acute ischemic symptoms; ischemic electrocardiogram changes; elevated cardiac biomarkers. Probable ST is any unexplained death within 30 days of stent implantation; any MI, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause. |
| Secondary | Number of Participants With Composite Endpoint of All-Cause Death or Myocardial Infarction (MI) | Baseline through 6 months | The endpoint in this measure is a combination of all-cause death or MI. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Composite Endpoint of Cardiovascular Death or Myocardial Infarction (MI) | Baseline through 6 months | Participants who were randomized. | participants | NUMBER |
| SECONDARY | Number of Participants With Stent Thrombosis (ST) | Baseline through 6 months | Participants who were randomized. | participants | NUMBER |
| SECONDARY | Number of Participants With Composite Endpoint of All-Cause Death or Myocardial Infarction (MI) | Baseline through 6 months | Participants who were randomized. | participants | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Composite Endpoint of Cardiovascular Death or Myocardial Infarction (MI) | Prasugrel | 0 | participants | ||
| Number of Participants With Composite Endpoint of Cardiovascular Death or Myocardial Infarction (MI) | Clopidogrel | 1 | participants | ||
| Number of Participants With Stent Thrombosis (ST) | Prasugrel | 0 | participants | ||
| Number of Participants With Stent Thrombosis (ST) | Clopidogrel | 0 | participants | ||
| Number of Participants With Composite Endpoint of All-Cause Death or Myocardial Infarction (MI) | Prasugrel | 0 | participants | ||
| Number of Participants With Composite Endpoint of All-Cause Death or Myocardial Infarction (MI) | Clopidogrel | 2 | participants |
Source ClinicalTrials.gov
Participant flow8
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Prasugrel | 212 | |
| Overall Study | STARTED | Clopidogrel | 211 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Prasugrel | 210 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Clopidogrel | 210 | |
| Overall Study | COMPLETED | Prasugrel | 136 | |
| Overall Study | COMPLETED | Clopidogrel | 137 | |
| Overall Study | NOT COMPLETED | Prasugrel | 76 | |
| Overall Study | NOT COMPLETED | Clopidogrel | 74 |
Source ClinicalTrials.gov
Adverse events412
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Prasugrel | 1 | 210 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | Clopidogrel | 0 | 210 | 0 |
| other | Spontaneous haematoma | Blood and lymphatic system disorders | Prasugrel | 6 | 210 | 6 |
| other | Spontaneous haematoma | Blood and lymphatic system disorders | Clopidogrel | 2 | 210 | 2 |
| other | Angina pectoris | Cardiac disorders | Prasugrel | 2 | 210 | 2 |
| other | Angina pectoris | Cardiac disorders | Clopidogrel | 1 | 210 | 1 |
| other | Atrial fibrillation | Cardiac disorders | Prasugrel | 2 | 210 | 2 |
| other | Atrial fibrillation | Cardiac disorders | Clopidogrel | 3 | 210 | 3 |
| other | Bradycardia | Cardiac disorders | Prasugrel | 1 | 210 | 1 |
| other | Bradycardia | Cardiac disorders | Clopidogrel | 0 | 210 | 0 |
1 to 10 of 412Source ClinicalTrials.gov
See all 412 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Prasugrel | ||
| Total, all-cause mortality | Clopidogrel | ||
| Total, other adverse events | Prasugrel | 110 | 210 |
| Total, other adverse events | Clopidogrel | 72 | 210 |
| Total, serious adverse events | Prasugrel | 40 | 210 |
| Total, serious adverse events | Clopidogrel | 38 | 210 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22520250 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Prasugrel vs Clopidogrel: Number of Participants With Composite Endpoint of Cardiovascular Death or Myocardial Infarction (MI) | Trial comparisons |
| Prasugrel vs Clopidogrel: Number of Participants With Stent Thrombosis (ST) | Trial comparisons |
| Prasugrel vs Clopidogrel: Number of Participants With Composite Endpoint of All-Cause Death or Myocardial Infarction (MI) | Trial comparisons |
| Prasugrel vs Clopidogrel: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00910299
GET https://conductscience.org/api/trials/v1/NCT00910299/events?page=2